Patent US641220A successfully refreshed from Google Patents.
Patent US4484923A successfully refreshed from Google Patents.
US4484923A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for administering immunopotentiator
Assignee: Alza Corp
•
Filing: 1984-01-05
•
Granted: 1984-11-27
•
Expires: 2004-01-05
Abstract
Abstract The invention pertains to the administration of an immunopotentiator to activate an immune response. The administration comprises the controlled and continuous administration of the immunopotentiator leading to a high immune response with adequate persistancy, while simultaneously and substantially reducing or eliminating inflammatory reactions usually accompanying depot-type administration.
Inventors
- 👤 Alfred A. Amkraut
- 👤 Agusto B. Martins
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 16:04
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0002; A61K9/0004; A61K39/00; A61K39/39; Y; Y02; Y02A; Y02A50/00; Y02A50/30
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
161 words
A method for potentiating the immune response of a host, which method consists essentially of administering to a host having an immune system and needing potentiation of its immune response, an immunopotentiating agent that is a member selected from the group consisting of an immunopotentiating lipid, immunopotentiating levamisole, immunopotentiating cord factor, immunopotentiating tilorane, immunopotentiating saponin, immunopotentiators prepared synthetically and derived from the endocrine system, immunopotentiators prepared synthetically and derived from the lymph system and immunopotentiators prepared synthetically and derived from the reticuloendothelial system, and wherein said agent is administered from a therapeutic delivery system that limits the contact of the host with the agent until the agent is released from the system, thereby lessening the incidence of local inflammation, fever and adverse biological response of the host to the agent, which agent is administered at a controlled rate and continously in a therapeutically effective amount of at least one picogram for a prolonged period of time for potentiating the immune response.
Claim 2
Independent Claim
161 words
A method for potentiating the immune response of a host, which method consists essentially of administering to a host having an immune system and needing potentiation of its immune response, an immunopotentiating agent that is a member selected from the group consisting of an immunopotentiating lipid, immunopotentiating levamisole, immunopotentiating cord factor, immunopotentiating tilorane, immunopotentiating saponin, immunopotentiators prepared synthetically and derived from the endocrine system, immunopotentiators prepared synthetically and derived from the lymph system and immunopotentiators prepared synthetically and derived from the reticuloendothelial system, and wherein said agent is administered from a therapeutic delivery system that limits the contact of the host with the agent until the agent is released from the system, thereby lessening the incidence of local inflammation, fever and adverse biological response of the host to the agent, which agent is administered at a controlled rate and continously in a therapeutically effective amount of at least one picogram for a prolonged period of time for potentiating the immune response.
Claim 3
Dependent Claim
30 words
The method for potentiating the immune response of a host according to claim 1, wherein the immunopotentiating agent is present in the therapeutic delivery system with a pharmaceutically acceptable carrier.
Claim 4
Independent Claim
141 words
A method for potentiating the immune response of a host, which method consists essentially of administering to a host having an immune system and needing potentiation of its immune response, an immunopotentiating agent that is a member selected from the group consisting essentially of an immunopotentiating lipopolysaccharide, immunopotentiating protein, immunopotentiating peptide, immunopotentiating peptidoglycan, immunopotentiating glycopeptides, immunopotentiating interferon, immunopotentiating lymphokines, and immunopotentiating muramyl peptide, and wherein said agent is administered from a therapeutic delivery system that limits the contact of the host with the agent until the agent is released from the system, thereby lessening the incidence of local inflammation, fever and adverse biological response of the host to the agent, which agent is administered at a controlled rate and continuously in a therapeutically effective amount of at least one picogram for a prolonged period of time for potentiating the immune response.
Claim 5
Independent Claim
141 words
A method for potentiating the immune response of a host, which method consists essentially of administering to a host having an immune system and needing potentiation of its immune response, an immunopotentiating agent that is a member selected from the group consisting essentially of an immunopotentiating lipopolysaccharide, immunopotentiating protein, immunopotentiating peptide, immunopotentiating peptidoglycan, immunopotentiating glycopeptides, immunopotentiating interferon, immunopotentiating lymphokines, and immunopotentiating muramyl peptide, and wherein said agent is administered from a therapeutic delivery system that limits the contact of the host with the agent until the agent is released from the system, thereby lessening the incidence of local inflammation, fever and adverse biological response of the host to the agent, which agent is administered at a controlled rate and continuously in a therapeutically effective amount of at least one picogram for a prolonged period of time for potentiating the immune response.
Claim 6
Dependent Claim
30 words
The method for potentiating the immune response of a host according to claim 1, wherein the immunopotentiating agent is present in the therapeutic delivery system with a pharmaceutically acceptable carrier.
References Cited (Backward Citations)
GB190925675A
Cited
US2332521A
Cited
US3135662A
Cited
US3075883A
Cited
US3493652A
Cited
US3452135A
Cited
US3522347A
Cited
US4004979A
Cited
US3993073A
Cited
US3859435A
Cited
US3678149A
Cited
US3752886A
Cited
US3964482A
Cited
US3837340A
Cited
US3787571A
Cited
US4057685A
Cited
US3767790A
Cited
US3814097A
Cited
US3867519A
Cited
US3888975A
Cited
US3971367A
Cited
US3993057A
Cited
US3811444A
Cited
US3916899A
Cited
US3923426A
Cited
US4138344A
Cited
US4140117A
Cited
US4002878A
Cited
US3937815A
Cited
US3995531A
Cited
US4122158A
Cited
US4164560A
Cited
US4166800A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-11-27 | 1988-05-28 | 1988-11-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-11-27 | 1992-05-28 | 1992-11-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-11-27 | 1996-05-28 | 1996-11-27 | $7700.00 | Window Closed / Lapsed |